Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NkartaNKTX +3.02%32 EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus rates NKTX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 943 Biotechnology companies, Nkarta ranks worse than 106044.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Nkarta's EBITDA for the
three
months ended in Jun. 2026 was $-40.40 Mil. Nkarta's Revenue for the
three
months ended in Jun. 2026 was $0.00 Mil. Therefore, Nkarta's EBITDA margin for the quarter that ended in Jun. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Nkarta EBITDA Margin % Related Terms
Nkarta EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Nkarta's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NKTX vs NRXP, YDES, TNXP: EBITDA Margin % Comparison
For the Biotechnology subindustry, Nkarta's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nkarta EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nkarta's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Nkarta's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nkarta (NKTX) has a EBITDA Margin % of 0.00% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nkarta and its competitors. According to the industry distribution chart, Nkarta ranks #999999 out of 943 companies in the Biotechnology industry.
Is Nkarta's EBITDA Margin % too high?
Nkarta's current EBITDA Margin % is 0.00%. Based on the distribution chart, Nkarta ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nkarta has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Nkarta's EBITDA Margin % compare to NRXP and YDES?
According to the Biotechnology industry distribution chart, Nkarta ranks #999999 out of 943 companies for EBITDA Margin %. This places Nkarta in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Nkarta and its competitors. Nkarta's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nkarta stock overvalued right now?
Nkarta (NKTX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Nkarta's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Nkarta (NKTX), the current EBITDA Margin % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
32GF Score
Get the complete analysis for NKTX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NKTX has been successfully added to your 
